Genome-wide interaction study with major depression identifies novel variants associated with cognitive function.

Area of Science:

• Neuroscience
• Genetics
• Psychiatry

Background:

• Major Depressive Disorder (MDD) is frequently linked to cognitive deficits.
• Understanding the genetic underpinnings of MDD and cognitive function is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the genome-wide interaction between MDD and cognitive function.
• To identify genetic factors contributing to cognitive dysfunction in MDD.
• To explore potential therapeutic targets for MDD-associated cognitive impairment.

Main Methods:

• Meta-analysis of genome-wide data from European cohorts (3510 MDD cases, 6057 controls).
• Polygenic Risk Score (PRS) analyses using data from the Psychiatric Genomics Consortium (PGC) for MDD, Bipolar Disorder (BD), Schizophrenia (SCZ), and Mood Instability (MIN).
• Gene expression analyses and Ingenuity Pathway Analysis (IPA®) for functional exploration.

Main Results:

• Identified significantly interacting single nucleotide polymorphisms (SNPs) between MDD and cognitive domains (executive function, processing speed, global cognition).
• Several identified SNPs are in genes crucial for brain functions like neuronal development (REST), oligodendrocyte maturation (TNFRSF21), and myelination (ARFGEF1).
• PRS for MIN and a meta-PRS for MDD, MIN, and SCZ were significantly associated with all cognitive domains.

Conclusions:

• Several genes involved in cognitive development and maintenance in MDD were identified.
• Potential novel therapeutic agents (e.g., vitamin D receptor, beta-estradiol, tadalafil) were highlighted for clinical exploration.
• The study provides a genetic basis for understanding and potentially treating cognitive dysfunction in MDD.